Navigation Links
Castrate resistant prostate cancer: New therapeutic approaches
Date:3/20/2009

Today Dr. Martin Gleave of the Vancouver Prostate Centre in Canada gave a lecture about new approaches to treat castrate-resistant prostate cancer (CRCP) during the 24th Annual Congress of the European Association of Urology in Stockholm, Sweden.

"If we look at the way kidney cancer treatment has changed over recent years we see a glimpse of the future", says Dr Gleave, "Targeted therapies may become available".

Recent studies indicate that tumour cells can develop an ability to synthesise enzymes to produce their own androgens for androgen receptor (AR) activation after castration.

CRPC tumours are not uniformly hormone resistant and may remain sensitive to therapies directed against the ARs. Dr Gleave: "Several new classes of AR-targeting agents are now in clinical development, including the 2nd generation anti-androgen MDV3100, abiraterone, and Hsp27 (OGX-427)".

The growth of new blood vessels, angiogenesis, plays an essential role in prostate cancer development and metastasis. "Among the various angiogenic targets implicated in tumour angiogenesis, vascular endothelial growth factor (VEGF), a potent angiogenic growth factor, and its receptor have evoked a lot of interest," according to Dr Gleave. Bevacizumab targets VEGF and is a promising angiogenesis inhibitor in this indication. Other agents in late stage trials include sunitinib.

Clusterin is a stress-induced, multi-functional, molecular chaperone. A novel, phase I pre-prostatectomy trial defined the optimal biologically dose and toxicity parameters of OGX-011 with maximal knockdown of clusterin in prostate and lymph node tissues at the 640 mg dose level. A phase II study includes 81 men with CRPC to receive either docetaxel and OGX-11 (n=40) or docetaxel alone (n=41).

"All in all, we need to move forward with the momentum and continue to let biology guide treatment developments", said Gleave, who also expressed his gratitude for being invited to speak at the 24th Annual EAU Congress.


'/>"/>

Contact: lindy brouwer
l.brouwer@uroweb.org
European Association of Urology
Source:Eurekalert

Related medicine news :

1. Recession-resistant Marketing Requires Innovative Steps
2. Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer
3. Mercy Hospital at Folsom Acquires Advanced Germicidal Technology to Battle MRSA, C. diff, Acinetobacter and Other Drug-Resistant Pathogens
4. Concerted Effort Needed to Fight Drug-Resistant Flu Strain
5. Antibiotic Combo Fights Resistant TB
6. A Recession-Resistant Business? Introducing FertilityAuthority.com
7. Antibiotic-Resistant Meningitis Reported in U.S.
8. Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients
9. Activity Against Drug-Resistant Pathogens is One of the Leading Attributes Influencing Physicians Antibiotic Selection for the Treatment of Inpatient Community-Acquired Pneumonia
10. Study shows rise in antibiotic resistant pediatric head and neck infections
11. A Study In This Months Journal Of Nervous And Mental Disease Reveals Hope For Recovery From Suicidal Thinking And Treatment Resistant Mental Illness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... ... of a new healthcare contact center in Georgia, PENETRON Specialty Products (PSP) provided ... nation’s largest healthcare systems recently invested $51 million to purchase and renovate the ...
(Date:2/22/2017)... ... February 22, 2017 , ... Stem ... recent years. The technology is so cutting edge, in fact, the U.S. Food ... stem cell procedures. However, successful patient outcomes in certain clinical stem cell procedures ...
(Date:2/22/2017)... ... 2017 , ... The National Academy of Certified Care Managers ... 2017 testing period. NACCM, a nonprofit organization, has provided the premier certification for ... periodically re-calibrated to ensure that newly certified professionals are prepared to work effectively ...
(Date:2/22/2017)... TX (PRWEB) , ... February ... ... Risk Adjustment solution leverages advanced data analytics to accurately understand each Medicare ... proper reimbursement for a given population. This new solution helps transform the ...
(Date:2/22/2017)... ... February 22, 2017 , ... Doctors on Liens is continuing its steady expansion ... H. Rauchman, practicing at North Valley Eye Medical Group in Mission Hills . ... and other personal injury cases. These injuries have a major impact on the ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Tillotts Pharma is strengthening its presence in ... office was opened in January 2017 under the management ... ® for the treatment of Crohn,s disease, Asacol ... VistaPrep ® for bowel preparation before endoscopy. With ... on the treatment of gastrointestinal (GI) diseases will expand ...
(Date:2/23/2017)... 23, 2017 The U.S. cannabis market ... for recreational use in 2016. According to a new report ... worth an estimated $7.2 billion in 2016 and is projected ... While adult recreational sales are projected to jump from $2.6 ... 25% CAGR. The market may grow faster as the estimate ...
(Date:2/23/2017)... , Feb. 22, 2017 Orthopedic ... implant demand, as aging demographic patterns lead to ... Implants for sports- and exercise-related injuries, chronic back ... will lead sales gains. The future of medical ... addresses the following questions and more: - ...
Breaking Medicine Technology: